MERCK KGAA

The North America IVD raw materials market, valued at USD 5,720.5 million in 2024, is projected to reach USD 15,385.3 million by 2033, growing at a CAGR of 12.6%. Factors driving growth include the rising prevalence of chronic diseases, advancements in diagnostic tools, and increased R&D investments. High production costs and regulatory hurdles restrain market expansion. Opportunities lie in growing R&D investments and advancements in molecular diagnostics and immunochemistry.

Europe IVD raw materials market valued at USD 4,231.3 million in 2024, projected to reach USD 10,486.2 million by 2033, growing at a CAGR of 12.9%. Driven by chronic disease prevalence, diagnostic tech advancements, and healthcare infrastructure investments. Key growth factors include personalized medicine demand and R&D activities. Regulatory challenges and high compliance costs hinder market entry for SMEs. Opportunities lie in personalized medicine trends and EU investments. Regional variations exist, with Germany, UK, France, Italy, Spain, and Netherlands leading in demand.

The global anatomic pathology market is growing due to the need for early disease detection. Key players include F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath S.p.A., Bio SB, Merck KGaA, BD, and PHC Holdings Corporation. The market is expected to reach US$ 53.27 billion by 2031 from US$ 30.22 billion in 2023, at a CAGR of 7.3%. Advances in AI and digital pathology are transforming the sector, with North America leading the market in 2023.

Iktos appoints a new Scientific Advisory Board with experts in AI-driven molecular design, lab automation, computational chemistry, first-in-human drug development, and strategic pipeline management to enhance its AI-first drug discovery platform.

The mRNA synthesis & manufacturing market is projected to reach USD 738.3 million by 2029, driven by mRNA vaccine development and technology advancements. Consumables dominate the market, with pharmaceutical and biotechnology companies leading as end users. Asia Pacific is expected to grow fastest due to increased healthcare expenditure and investments in biopharmaceuticals.

Transgene's Phase II trial of viral-based vaccine TG4001, combined with Bavencio, failed to meet primary endpoint of PFS in solid tumours, causing a stock drop. However, a positive trend was observed in cervical cancer patients, prompting further analysis. The company remains focused on its personalized cancer vaccine TG4050.

BioDuro-Sundia launched a state-of-the-art Compound Management Center in Shanghai to enhance drug discovery capabilities, offering secure storage, real-time inventory tracking, and rapid sample access. The center aims to expedite R&D, reduce costs, and accelerate therapy candidate discoveries.

Transgene's TG4001 vaccine for cervical and anogenital cancers failed to meet primary PFS objective in phase 2 trial, but showed a trend towards improvement in cervical cancer subgroup, requiring further analysis. TG4001 uses a Modified Vaccinia virus Ankara vector with HPV E6, E7 antigens, and human IL-2. The company plans a full data analysis before deciding the future of TG4001, while focusing on its other vaccine programs, including TG4050 for head and neck cancer.

The global cancer gene therapy market is projected to grow from USD 1,822.2 million in 2024 to USD 3,142.2 million by 2034, driven by increased R&D funding, rising cancer prevalence, and favorable government regulations. Oncolytic virotherapy, a key segment, generated USD 850.7 million in 2023. The market is shifting towards personalized, targeted therapies, reducing side effects and improving outcomes.

Transgene's share price dropped 15% after announcing the failure of its Phase II TG4001 trial for cervical and anogenital cancers. The trial did not meet its primary endpoint of improving progression-free survival. Transgene's strategy now focuses on the development of TG4050, a therapeutic vaccine for head and neck cancer.